DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma

Zhao, Wei; Tian, Bo; Wu, Chao; Peng, Yan; Wang, Hui; Gu, Wenli; Gao, Feng‐Hou

doi:10.1016/j.prp.2014.12.014

Cited by 48 publications

(40 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, while MTHFD2 can hardly be detected in papillary or chromophobe RCC, vimentin expression was also significantly associated with clear cell RCC in our experiments. Actually, vimentin has been proven to be a marker that can distinguish chromophobe RCC from clear cell RCC and renal oncocytoma [19,20]. However, due to an insufficient number of samples of the other two types of RCC in our trial, we were unable to determine definitively the expression pattern of MTHFD2 in different pathological types of RCC.…”

Section: Mthfd2 Down-regulation Sensitizes 786-o Cells To Chemotherapmentioning

confidence: 87%

MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion

Lin

Huang

Wang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: To investigate the role of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) in the clinical prognosis and cell biology of renal cell carcinoma (RCC). Methods: A total of 137 RCC tissues were evaluated by immunohistochemistry. The relationship between MTHFD2 overexpression and clinical parameters and vimentin expression was assessed. Kaplan-Meier curves and the log-rank test were applied for survival analysis according to MTHFD2 and vimentin expression in RCC tissues. The expression of MTHFD2 mRNA and protein was examined by quantitative reverse transcription PCR and western blotting, respectively. To determine further the biological activity of MTHFD2 in RCC, 786-O cells were transfected with short hairpin RNA specifically targeting MTHFD2 (shMTHFD2) with or without tumor necrosis factor (TNF)-α stimulation. Cell proliferation, cell migration and invasion and drug sensitivity were subsequently assessed using Cell Counting Kit-8, wound healing, and Transwell assays. Results: Immunohistochemical analysis demonstrated that both MTHFD2 and vimentin overexpression was positively associated with clinical staging, pathological grade, and poor overall survival (all P < 0.05). MTHFD2 expression was closely correlated with vimentin overexpression in RCC (r = 0.402, P < 0.001). After knocking down MTHFD2 expression in 786-O cells, decreased cell proliferation, migration, and invasion were observed and accompanied by the reduced expression of vimentin. The effects of MTHFD2 down-regulation could be partially restrained by TNF-α treatment. Vimentin expression and cell migration and invasion, but not cell proliferation, were reversed by TNF-α stimulation. Furthermore, treatment of 786-O cells with shMTHFD2 increased their sensitivity to chemotherapy drugs. Conclusion: The current results demonstrated that MTHFD2 was overexpressed in RCC and associated with poor clinical characteristics, vimentin expression, and cellular features connected to malignant disease, thus, implicating MTHFD2 as a potential target for RCC therapy.

show abstract

Section: Mthfd2 Down-regulation Sensitizes 786-o Cells To Chemotherapmentioning

confidence: 87%

MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion

Lin

Huang

Wang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…In testicular tissues, DOG1 immunoreactivity is observed in spermatocytes, spermatids and the luminal borders of the epididymis and rete testis . The various tumor types reported to express DOG1 are presented in Table . In particular, DOG1 immunoexpression in salivary gland tumors has been investigated in detail, and DOG1 has been practically applied as a marker of salivary acinar and intercalated duct differentiation .…”

Section: Dog1 Immunohistochemical Expression In Various Tumor Types Omentioning

confidence: 99%

The role of DOG1 immunohistochemistry in dermatopathology

Goto

2016

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…Other important mutations are found in 23.9% of p53 or 10.9% of BHD (Birt-Hoge-Dubé) [27]. Chromophobe RCC is distinctively, in a true sense, an epithelial-friendly tumor in viewpoint of IHC [32,33]. We also suggest that CD10 and AMACR aberrant expression can be a predictor of aggressive behavior in ChRCC in addition to the known factor of sarcomatoid differentiation [34,35].…”

Section: Discussionmentioning

confidence: 72%

Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes

Kim

Joo

Lee

et al. 2020

Cancers

View full text Add to dashboard Cite

In recent years, renal epithelial tumors have been among the fastest reclassifying tumors, requiring updates to the tumor classification system. Nonetheless, immunohistochemistry (IHC) remains the most widely used tool for renal epithelial tumors. In this proposal, we aimed to create the most efficient IHC panel for categorizing the diverse subtypes of renal tumors, and to find out more specific immunohistochemical results in each subtype or each antibody. A total of 214 renal tumors were analyzed using 10 possible IHC markers to differentiate subtypes, including three major renal cell carcinoma (RCC) subtypes, clear-cell type (50 cases), papillary type (50 cases), and chromophobe type (20 cases), and minor subtypes (MiT RCC, 13 cases; collecting duct carcinoma, 5 cases; and oncocytoma, 10 cases). A triple immunomarker (cytokeratin 7 (CK7)-carbonic anhydrase IX (CAIX)- alpha-methylacyl-CoA racemase (AMACR)) panel is useful in particular high-grade clear-cell tumors. If IHC remains ambiguous, the use of an adjunctive panel can be suggested, including CD10, epithelial membrane antigen, cathepsin K, c-kit, hepatocyte nuclear factor 1-β, and E-cadherin. For an efficient immunohistochemical strategy for subtyping of RCC, we conclude that the CK7-CAIX-AMACR panel is the best primary choice for screening subtyping.

show abstract

DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma

Cited by 48 publications

References 25 publications

MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion

MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion

The role of DOG1 immunohistochemistry in dermatopathology

Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes

Contact Info

Product

Resources

About